Page last updated: 2024-09-04

canertinib and pd 166326

canertinib has been researched along with pd 166326 in 1 studies

Compound Research Comparison

Studies
(canertinib)
Trials
(canertinib)
Recent Studies (post-2010)
(canertinib)
Studies
(pd 166326)
Trials
(pd 166326)
Recent Studies (post-2010) (pd 166326)
1249652002

Protein Interaction Comparison

ProteinTaxonomycanertinib (IC50)pd 166326 (IC50)
Tyrosine-protein kinase ABL1Homo sapiens (human)0.0054
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)0.006
Epidermal growth factor receptorHomo sapiens (human)0.093
Platelet-derived growth factor receptor betaMus musculus (house mouse)0.21
Tyrosine-protein kinase LckHomo sapiens (human)0.0432
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0781
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.636
Fibroblast growth factor receptor 1Homo sapiens (human)0.0739
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)0.0646
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.092
Mitogen-activated protein kinase 14Homo sapiens (human)0.14

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bharate, SB; Raghuvanshi, R1

Other Studies

1 other study(ies) available for canertinib and pd 166326

ArticleYear
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022